

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:

Mercy Hospital Springfield
1235 East Cherokee Street & 2115 S. Fremont Ave.
Springfield, Missouri

REPORT NUMBER(S) 2015-002

2. NRC/REGIONAL OFFICE

Region III
U. S. Nuclear Regulatory Commission
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352

3. DOCKET NUMBER(S)

030-02285

4. LICENSE NUMBER(S)

24-00866-02

5. DATE(S) OF INSPECTION

August 5, 2015

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

- ☒ 1. Based on the inspection findings, no violations were identified.
- ☒ 2. Previous violation(s) closed.
- ☐ 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.

Non-cited violation(s) were discussed involving the following requirement(s):

- ☐ 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.
(Violations and Corrective Actions)

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Robert G. Gattone, Jr.	<i>Robert G. Gattone, Jr.</i>	8/27/15
BRANCH CHIEF	Aaron T. McCraw	<i>[Signature]</i>	8/28/15

Docket File Information

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: Mercy Hospital Springfield 1235 East Cherokee Street & 2115 S. Fremont Ave. Springfield, Missouri REPORT NUMBER(S) 2015-002	2. NRC/REGIONAL OFFICE Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352
---	---

3. DOCKET NUMBER(S) 030-02285	4. LICENSE NUMBER(S) 24-00866-02	5. DATE(S) OF INSPECTION August 5, 2015
6. INSPECTION PROCEDURES USED 87130	7. INSPECTION FOCUS AREAS IP 87130: 02.01-02.07	

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S) 02230	2. PRIORITY 2	3. LICENSEE CONTACT Nick Lannutti, RSO	4. TELEPHONE NUMBER (417) 820-7704
---------------------------------	----------------------	---	---

☒ Main Office Inspection Next Inspection Date: No Change

☐ Field Office Inspection _____

☐ Temporary Job Site Inspection _____

PROGRAM SCOPE

This was Part 2 of the routine inspection that began on April 1, 2015. Specifically, this inspection included the facility at 2115 S. Fremont Avenue and it included follow up of violations that were identified as a result of Part 1 of the routine inspection that began on April 1, 2015. As such, the next inspection date should not be changed as a result of this inspection. The licensee had not used Y-90 SIR-Spheres yet, but it planned to do so soon at the authorized location. Licensed activities conducted at the 2115 S. Fremont Avenue facility were limited to using technetium-99m labeled radiopharmaceuticals (unit dosages) for cardiac Multi-Gated Acquisitions (a.k.a. MUGAs) and cardiac perfusion studies between 6:00am and 4:00pm Monday through Friday. About 10 imaging studies were done daily. At the 1229 E. Seminole Street facility, Sentinel Node localization studies were conducted with technetium-99m labeled radiopharmaceuticals; however, none were done during the onsite inspection.

Performance Observations

The inspector: (1) observed that licensed material was secured in the hot lab as required; (2) observed a nuclear medicine technologist (NMT) demonstrate how packages were received including, in part, use of dosimeter badges, doing a survey instrument operability check, and conducting surveys, as required; (3) observed an NMT demonstrate how he prepared an LQ package for transfer; (4) used an NRC owned, calibrated survey instrument to measure a maximum of 0.2 milliroentgen per hour (mR/hr) at the surface of a check source and the licensee got a similar measurement using a licensee survey instrument that was calibrated as required; (5) observed an NMT demonstrate how he would respond to a radioactive spill based on a scenario posed by the inspector; (6) used an NRC owned, calibrated survey instrument to measure a maximum of 0.2 mR/hr behind an L-block near shielded unit dosages; (7) observed an NMT demonstrate how end of day area surveys were done; (8) observed an NMT prepare a Myoview unit dosage for administration while using gloves, syringe shield, unit dosage shield and dosimeter badges; (9) observed an NMT administer Myoview to a patient using, in part, a syringe shield; (10) observed a locked drawer that was limited to authorized persons where sentinel node localization study unit dosages containing 500 microcuries of technetium-99m labeled radiopharmaceuticals were secured as required; (11) interviewed a registered nurse (RN) about how sentinel node localization studies were conducted at the 1229 E. Seminole Street facility and noted, in part, that the RN used proper personal protection equipment, an authorized user prescribed the dosages, and a DOT Type A package was used for transporting dosages to and from the location of use.